Abstract
Cannabis Hyperemesis Syndrome (CHS) is characterized by persistent nausea, vomiting and abdominal pain with episodes of cyclic vomiting associated with chronic cannabis use. CHS symptoms are difficult to manage and are often refractory to standard first-line antiemetics and analgesics. Recent prospective studies have demonstrated the superiority of haloperidol, a dopamine antagonist, over ondansetron for the treatment of CHS. Interim analysis of our study has determined that droperidol, also a dopamine antagonist, has equal or better efficacy to haloperidol.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
